#sarah peddicord | Explore Tumblr Posts and Blogs

Visit Blog

Explore Tumblr blogs with no restrictions, modern design and the best experience.

Fun Fact

1,644 Tumblr posts in 1 second.

urbanhermit · 2 years

Photo

(Part 1) ‘Soldiers of God In A Secular World: Catholic Theology & 20th Century French Politics’ (2021) by Sarah Sortall is a good follow to ‘The Sacred Monster of Thomism’ (2005) by Richard Peddicord, OP. Sortall uncovers how ‘nouvelle thologie’ (‘new theology’) developed in the 1930s & ‘40s. Born from the ashes of the anticlerical campaign by the French Republic. The French Republic officially proclaimed the separation of church & state in 1905, roughly 30,000 religious were exiled. The Jesuits were already exiled by the Republic in 1880. The Jesuit scholastic of Laval moved to the island of Jersey off the coast of Normandy. The theologate to Ore Place, Hastings, England. The Dominicans moved their Parisian Studium to Le Saulchoir in Kain, Belgian. Their isolation would draw both orders to a powerful critique of the dominant brand of neo-Thomism by turning back to the earliest sources of the Catholic tradition: St Paul & the Church Fathers. https://www.instagram.com/p/CdVilGiszHx/?igshid=NGJjMDIxMWI=

0 notes

thesiteofstyle · 7 years

Photo

SARAH PEDDICORD

We caught up with jewelry designer of ISL MALIBU on her beach essentials and her sources for inspiration...

What do you bring on a trip to the beach?

“To a beach trip I would typically bring a couple rompers (overalls) or dresses that you can slip on and maybe 1 or 2 pairs of shorts with some playful shirts as well. However where I live, whenever I go to the beach, I wear a big shirt over my bathing suit. I am a sunglass hoarder so I have almost 5 pairs just in my purse. They are a must when I go to the beach, but my favorites are my Wildfox sunnies, Elizabeth+James, or my pair of Ray-Bans. I live in Malibu so there are a lot of beach stores, but I wear a trucker hat from a store here that all the locals have as well. I have a couple floppy hats that I got online as well and a hat from Zara that I love. Bikinis are all everyone wears in Malibu, so besides sunglasses, I hoard bathing suits. My favorite brands are Mikoh, Boys+Arrows, L-Space, Acacia, Made By Dawn, Bubululu, Triangl, and Tori Praver. Planet Blue is the best place to shop at for beach trips, so that’s where I get most of my beach attire.”

Where do you draw style inspiration from?

“My style is inspired by pretty much anyone I see on any fashion blogs, but the street style of Rosie Huntington-Whiteley, the Olsen twins, and Ashley Benson best fit me because they all wear simple, chic, and comfy outfits, yet a little bad-ass looking at some times.

Style to me is a representation of your mood. Even though you put together an outfit to go out and then you come home and take it off, it’s a way of presenting yourself to other people and it’s almost like a collaboration of art pieces. Clothing is so valuable to me because I am always on the fashion “alert” of what the newest trends are and what is the new buzz in the fashion world, but I see style as a form of art.”

Interviewed and written by Kara Smith

Images c/o Sarah Peddicord and ISL MALIBU

#sarah peddicord #interviews #fashion #FeaturedPost

2 notes · View notes

clavehell6-blog · 5 years

Text

Movers & Shakers: CBRE promotes Robert Peddicord, 3 Agency brokers jump ship…and more

SRS Real Estate Partners also tapped Mike Reilly to lead new operation, SRS Signature Group

From left: Danny Brown and Robert Peddicord (Credit: iStock)

CBRE tapped Robert Peddicord to lead the firm’s South Bay operations, overseeing a 130-person office in El Segundo. Peddicord, who has been at the firm since 2012, is succeeding Jodie Poirier. In his new capacity, effective Jan. 1., he will oversee the advisory, transactions, capital markets and asset services operations at the firm. He served as executive managing director of institutional services for L.A. and Orange counties prior to the promotion.

Danny Brown, a residential agent specializing in the Westside, has left the Agency to join Compass. Brown joined the Agency as a partner in 2016. He recently represented HGTV in their high-profile purchase of the iconic Studio City home used to film the “Brady Brunch.” Brown is also bringing Sarah Mohageri, his director of operations, to Compass. They will be based in Compass’s Beverly Hills office.

Two other agents — Leonard Rabinowitz and Jack Friedkin — also left the Agency recently. The duo is now at Hilton & Hyland. In an email, Rabinowitz said they left because they wanted to be at a “boutique agency and the Agency is going global.” They are currently listing Frank Sinatra’s former beach house in Malibu, seeking $12.9 million. The team is also listing the Chimorro house, designed by Roy Seldon Price.

NAI Capital is following in Kidder Mathew’s footsteps and has recruited some former Charles Dunn brokers. The firm has hired Chris Runyen, Faye Montgomery, Michael Vera and Tracy Taft to join its Downtown Los Angeles office. Taft was named vice president, while the remaining three were given senior vice president titles. Their old shop — Charles Dunn — closed its brokerage division in early November, prompting a wave of departures.

SRS Real Estate Partners, based in Dallas, is expanding in L.A. The firm hired Mike Reilly to lead SRS Signature Group, a new service offering that will target domestic and international brands. Reilly will also serve as senior vice president and managing principal at the firm’s new L.A. office, slated to open in early 2019. With a focus on retail, he’s represented companies like Uniqlo, Scotch & Soda, True Religion, Fred Segal, among others. Previously, he worked as president of Next Wave Retail.

Source: https://therealdeal.com/la/2018/12/20/movers-shakers-cbre-promotes-robert-peddicord-three-agency-brokers-jump-ship-and-more/

0 notes

azveille · 5 years

Text

How a Tainted Heart Drug Made in China Slipped Past the FDA

A Chinese-made heart drug taken by millions of people was contaminated with a possible cancer-causing chemical.

The Food and Drug Administration oversaw a recall of the tainted pills. But even as it did so, the agency that helps safeguard a global supply chain of drugs was conducting fewer inspections of pharmaceutical plants in the country where the problem originated.

Treatments made by Chinese companies now account for almost one of every 10 generic drugs cleared by the FDA for sale. But agency inspections meant to ensure that approved drugs are meeting U.S. standards fell almost 11 percent, to 125, in China for the fiscal year that ended Sept. 30, compared with the previous year, according to data obtained by Bloomberg through public-records requests.

Using hundreds of pages of the U.S. government documents, Bloomberg has spent the last year reporting on a supply chain that reaches around the world and ends inside American medicine cabinets. While overall inspections of that network are down, records show that those that do get done—from West Virginia to China and India—raise doubts about the data meant to prove drugs are safe and effective.

Those doubts are sometimes overruled by FDA management. At the plant that set off the heart-drug recall in July of last year, an FDA inspector had determined in May 2017 that some of the drugs it was supplying to the American market might be substandard, according to an inspection report obtained by Bloomberg.

The FDA inspector’s 2017 visit had turned up a number of problems. The Chinese drugmaker, Zhejiang Huahai Pharmaceutical Co. Ltd., had omitted from official records quality-test results that showed unnamed drugs failed to meet U.S. standards, and instead recorded passing grades, the FDA inspector wrote in his report. The inspector recommended that the agency send Zhejiang Huahai, one of China’s largest exporters of pharmaceuticals, a warning letter that likely would have meant it couldn’t gain approval to make any new generic drugs in that factory until it cleared up the list of problems.

But four months later, FDA managers at the agency’s Silver Spring, Maryland, headquarters overruled the inspector. Zhejiang Huahai Pharmaceutical was allowed to avoid those penalties and address the problems itself—possibly missing a chance to detect the cancer-causing contaminant more than a year earlier than it was.

“That’s not OK to just wave it off,” Kevin Schug, an analytical chemistry professor at the University of Texas at Arlington, said after reading the inspection report at the request of Bloomberg. Schug specializes in the type of testing that drug companies use to conduct quality checks. “I certainly would not want to take [any] drug had it gone through that process.”

The High Cost of Cheap Pills A year-long investigation by Bloomberg News into the generic-drug industry shows FDA inspections at factories from West Virginia to China have found reason to doubt the data meant to prove drugs are safe and effective. This is the second of four parts.

America’s Love Affair With Cheap Drugs Has a Hidden Cost

Culture of ‘Bending Rules’ in India Challenges U.S. Drug Agency

An FDA spokeswoman, Sarah Peddicord, said patient safety dictates the agency’s response. After the 2017 inspection uncovered the problem with impurities, “FDA reviewed the inspectional findings and considered the company’s proposed corrective actions when deciding what action to take.”

More and more medications that Americans consume are coming from China, where production costs are lower. Chinese-made drugs accounted for 8 percent of FDA generic approvals in 2018 through Oct. 30, up from 1 percent in 2015, according to Morris Borenstein, a senior Moody’s analyst.

Yet inspections of generic makers in China have fallen. The recent decline pushed the number of FDA inspections in the country below what they were a few years ago, when the agency vowed to beef up its overseas capability. President Donald Trump’s FDA commissioner, Scott Gottlieb, has made ushering more generic drugs to market a priority as part of the president’s effort to lower prices.

In defending his agency’s approach, Gottlieb said it uses a formula that weighs risk factors, including when a factory was last inspected and what the inspection found—not geography.

“If you’re thinking about this from a risk standpoint—from the people that do the intelligence work that know where the risks are—it's not just that we've done x number of inspections over x number of years of x number of facilities,” Gottlieb said in an interview. “The points of risk change as the nature of the supply chain has changed.”

So-called surveillance inspections done in fiscal 2017, which included Gottlieb’s first few months in office, totaled 140 in China, a 14 percent decrease from the 163 the FDA did in fiscal 2016. The agency uses surveillance inspections to ensure companies are complying with U.S. manufacturing standards and to verify the accuracy of companies’ internal quality tests.

FDA drug-quality inspections fell 23 percent from fiscal 2016 to fiscal 2018

In an update on the heart-drug recall Friday, the FDA said any additional inspections should focus not on a particular country, but on facilities that make the treatment, which goes by the name valsartan. “We remain confident in the use of FDA’s current risk-based approach, which does not include geographic location as a risk factor, and in our continuing ability to protect patients from products that have the potential to cause harm,” the agency said.

Zhejiang Huahai didn’t respond to questions about whether it could have found the potential carcinogen, a chemical called NDMA, sooner. Jun Du, chief executive officer of Zhejiang Huahai subsidiary Prinston Pharmaceutical Inc., said in an email that the FDA closed its 2017 inspection of the Chinese plant after the company submitted detailed responses to the inspector’s observations.

“At all times from the inception of the recall, we have been in close communication with the FDA, and have collaborated throughout with agency staff, our customers and patients,” Du said.

Zhejiang Huahai was supplying the active-ingredient valsartan—a widely used treatment for high blood pressure that is taken alone, as well as sold in combination with other cardiovascular drugs—for major companies such as Teva Pharmaceutical Industries Ltd., the largest generic drugmaker in the world. After the FDA flagged the contamination problem, Teva in July started recalling valsartan and valsartan combined with other drugs. Since then, other companies have recalled it as well, including some that didn’t purchase valsartan from Zhejiang Huahai, such as Mylan NV, the second-largest generic-drug company, for containing a similar cancer-causing ingredient, NDEA.

Zhejiang Huahai has had problems with its data before. In 2016, Chinese regulators asked drug makers to withdraw any applications to sell new drugs that may have contained false or incomplete data. Zhejiang Huahai pulled its applications for generics for epilepsy, blood pressure and depression, saying at the time that the issues related to flawed testing by a local Chinese contract research organization, affiliated with a major hospital in China.

The increasing number of companies buying their ingredients from China raises concerns that such problems are more widespread, said Randall Zusman, director of the hypertension division at Massachusetts General Hospital Heart Center.

“I found it surprising that Teva, which has their own manufacturing plants, was buying the Chinese valsartan for their products,” Zusman said. “They found it economically appropriate to buy from this Chinese supplier, which shows just how widespread this could become if that continues to be the case.”

Zusman said one of his colleagues consulted him about a patient who developed bladder cancer while taking valsartan. It’s unclear if the valsartan contributed to the cancer, Zusman said, but it's a concern. “Obviously, it’s very scary to the patient,” he said. “And it’s disillusioning to me to think that I might have prescribed a drug that could have caused a malignancy.”

He is currently not starting any of his patients on valsartan. While there are alternatives, the recall has raised doubts in his mind about the drug.

“I am rethinking every time I’m prescribing one of these,” Zusman said of valsartan products.

“They certainly should have caught it, and they should have modified the procedure to correct it”

The FDA inspector who visited Zhejiang Huahai’s factory in the city of Linhai wrote in his inspection report that the company has a practice of recording passing scores for drugs that originally fell short of U.S. standards on routine quality tests. He said his findings cast “a cloud of uncertainty over the accuracy of test results” that are used to gain clearance to sell drugs in the U.S., according to documents from the public-records request.

The quality tests, which are standard practice in pharmaceutical manufacturing, check for the amount of active ingredient in a drug and scan for potential contamination. The FDA inspector recommended the company be given a warning letter, one of the FDA’s strongest rebukes: It can set in motion restrictions on whether a company can sell products in the U.S. Companies that get warning letters also often have to undergo rigorous evaluation of their testing methods.

According to a memo obtained through the public-records requests, the FDA managers who overrode the inspector’s concerns about Zhejiang Huahai decided to let the company correct its problems, choosing not to place any restrictions on the drugmaker. The FDA managers said that the agency had found no violations during inspections in 2010 and 2014, and that the test results in question hadn’t affected the final products.

About a year after the inspector’s concerns were overruled, a company that buys valsartan from Zhejiang Huahai spotted an impurity in the Chinese company’s active ingredient that was discovered to be the potentially cancer-causing chemical NDMA. Zhejiang Huahai’s plant that makes valsartan was then banned from sending drugs to the U.S. (The FDA didn’t identify the customer that discovered the impurity.)

The FDA inspector who originally visited the factory had written in his report that the failed quality tests the company had omitted from official records included ones that flagged impurities in unnamed drugs that the company didn’t attempt to identify.

Zhejiang Huahai was supposed to figure out how to identify the impurities or get rid of them, said Schug, the analytical chemistry professor. If NDMA was being introduced or created during the manufacturing process, testing would likely identify it, he said.

“They certainly should have caught it, and they should have modified the procedure to correct it,” Schug said.

Zhejiang Huahai didn’t comment on specific questions about the failed testing. Inspectors revisited the Linhai factory in July and August, after the valsartan recall started. The FDA again found Zhejiang Huahai had omitted tests that flagged unknown impurities, according to a warning letter the agency sent the company Nov. 29.

The letter stated that if Zhejiang Huahai “had investigated further,” workers may have found indicators “alerting you to the presence of NDMA.” The FDA also said in the letter that it had “grave concerns” about the presence of potentially cancer-causing impurities in all pharmaceutical ingredients manufactured by Zhejiang Huahai, not just valsartan.

Zhejiang Huahai has cooperated with the FDA throughout its investigation, said Du, the Prinston chief executive officer. “In detailed analyses and corrective action plans, the company has been and is currently addressing each of the FDA’s 2018 observations, as well as items noted by the FDA more recently in its warning letter,” he said.

Since the revelation that Zhejiang Huahai’s valsartan contained NDMA, the FDA has repeatedly updated the recall notice as new samples of valsartan—and even similar drugs called losartan and irbesartan—are found to be contaminated. The agency is attempting to determine how the chemical made its way into the products and is reviewing the companies’ manufacturing processes to determine if they might risk forming NDMA or NDEA.

Not all the companies that have recalled the drug received it from Zhejiang Huahai, but manufacturers of the recalled valsartan products used a similar process to make the pills. That process is different from the brand-name version of valsartan called Diovan, made by Swiss drugmaker Novartis AG. Diovan hasn’t been found to contain NDMA or NDEA and hasn’t been recalled.

Zhejiang Huahai’s valsartan contained “significantly higher” levels of NDMA than other recalled versions of the drug, the FDA said in its November warning letter.

U.S. regulators expect companies to police themselves. “The FDA’s review of records relies on manufacturers conducting appropriate tests that are capable of detecting impurities,” said Peddicord, the agency spokeswoman. “It is the manufacturer’s responsibility to ensure these tests are based on adequate assessments of what impurities are expected to develop during the manufacturing process.”

The agency said it has been working with valsartan makers affected by the recall “to minimize or eliminate” the risk of forming probable cancer-causing impurities.

In the case of Zhejiang Huahai, the company had last made changes to its processes in 2011, according to the FDA. And the agency said the potential carcinogen may have been in the valsartan for as long as four years.

0 notes

cool-groovyfirebouquet-blog · 6 years

Text

Not known Facts About cosmetic medicine

youtube

We put on our feelings on our confront and typical actions like frowning, squinting or getting indignant cause the muscles beneath the skin between our brows to agreement. With medical skin clinic ottawa bring about the skin that covers the muscles to move likewise, at some point "A separate balancing of dangers and Added benefits is needed for Every intended use of a drug, even at the time it is accredited, to make sure the benefits of utilizing the solution to treat a specific disorder or condition outweigh the dangers," says FDA push officer Sarah Peddicord. BOTOX COSMETIC® is a unique prescription product and also a registered trademark. To make certain it’s BOTOX COSMETIC®, request it by title much like millions of Other individuals have. BOTOX® Cosmetic is Just about the most extensively studied medical aesthetic treatment options and it is approved for cosmetic use in 78 countries.* BOTOX® Cosmetic features a file of experience that aesthetic experts know and belief. And, the protection and efficacy of BOTOX® Cosmetic have already been evaluated in equally Allergan sponsored clinical trials in addition to in 417 peer-reviewed articles in scientific and medical journals. Concept Medical 11 Holland Ave., Suite 400 Ottawa, ON K1Y 4S1 Canada (613) 829-1266 At your session: It’s a good idea to deliver some questions alongside towards the consultation. Because BOTOX is actually a prescription drug, you’ll meet up with which has a accredited doctor to discuss your ambitions for that treatment. They are a purified sort of botulinum toxin A, which means there is no botulism threat when used appropriately. They operate by blocking the nerves that agreement muscles, softening the looks of wrinkles. The outlawed customized continues to be sometimes encountered typically in rural locations. The society at big and The federal government are Doing the job to finish the exercise of ostracizing widows.[eight] Additionally, it continues to get popular apply for men to shave their heads ahead of embarking on the pilgrimage. Ironically, it's the off-goal consequences of Botox that have some scientists most energized. "Botox could possibly be Operating in a method that is different from what we predict," suggests Bomba-Warczak. "It could be far more intricate." Other folks reported that off-label drug use is largely fiscally motivated Which it poses a significant risk to community wellness, specially when medications are applied experimentally on small children. Your professional may possibly use ice to numb the cure region. If you're worried about soreness, your expert may perhaps utilize a topical numbing product in advance of administering your therapy. The particular injection process usually takes about 10 minutes Your professional will focus on your remedy aims and carry out a facial Investigation to ascertain the appropriate cure places in your case. These are frequently the most important wrinkles with your experience and the ones that may cause you to glimpse the oldest. The toxin commences to get result many days just after your injections. If a doctor notices that, say, a therapy for crossed eyes also "requires the strains out," he might mention it on the representative from whom he buys the medicine. That rep may share that with Yet another of his clientele, etc. At Epiderma, we are aware that each of our clientele is unique and has particular needs. Read More Here why we offer designed-to-measure provider. Your session will incorporate a health and fitness assessment to ensure your secure therapy plan is good for you. Muscle mass spasms can vary from minimal, aesthetically unpleasing facial tics to severe, debilitating ailments that lower the sufferer’s In general quality of life. These spasms are a result of a selection of various genetic and personal variables — dehydration, mineral deficiency, overburdened muscle teams plus more — but can all usually be treated by permitting only one muscle mass or a bunch of muscles to halt regularly contracting.

check here -75.7336101!3d45.4032598!3m2!1i1024!2i768!4f13.1!3m3!1m2!1s0x0%3A0xf07921c1a002efb2!2sConcept+Medical!5e0!3m2!1sen!2sph!4v1516062779712" width="600" height="450" frameborder="0" style="border:0" allowfullscreen>

0 notes

urbanhermit · 2 years

Photo

[Part 1] I finished ‘The Sacred Monster of Thomism: An Introduction to the Life & Legacy of Reginald Garrigou-Lagrange, OP’ (2005) by Richard Peddicord, OP. Fr. Peddicord, OP was President of Aquinas Institute of Theology in St Louis 2008-2012. Lagrange was professor of dogmatic & spiritual theology at the Angelicum in Rome from 1909-1959. He died early in 1964 a year before Vatican II ended. He has a bibliography of over 50 pages. Chapter 4 deals with his disputations with the philosophies of Henri Bergson & Maurice Blondel & why he opposed them. Chapter 5 deals with his Politics & the conflict it bred for him against Jacques Maritain & Marie-Dominique Chenu, OP. These two chapters are what attracted me to this work. Francois Maurac expressed his disdain for Lagrange, calling him ‘that sacred monster (monstre sacre) of Thomism’. A sentiment that has held the day: identifying his theological rigidity & ecclesiastical repression. This work is an introduction to the life & thought of Lagrange. There is some truth in the oft-repeated line that Lagrange’s favorite sparring partners were dead philosophers & live Jesuits! (Teilhard de Chardin, Henri de Lubac, Jean Danielou, etc.) Lagrange is put into the ‘strict-observance Thomist’ category. Which was a standard way of speaking about the Thomists who taught in the Roman Universities up to Vatican II. He served as advisor to a myriad of doctoral candidates at the Angelicum. Two of note, M-Dominique Chenu, OP, & Karol Wojtyla – the future John Paul II. Lagrange was consulted numerous times by the Holy Office on doctrinal matter. In Rome speak, he was a ‘qualificator’ – one who was qualified as a theological authority. Serving from the pontificate of Benedict XV to John XXIII. In 1955 he was named a ‘consultor’ for both the Holy Office & for the Congregation for Religious. He died 15 February 1964 on the feast of the 14th-century Dominican Rhineland mystic, Blessed Henry Suso, OP. I now begin ‘Soldiers of God In a Secular World: Catholic Theology & 20th-Century French Politics (2021) by Sarah Shortall. https://www.instagram.com/p/CdMgBLXLjlX/?igshid=NGJjMDIxMWI=

0 notes

Last Seen Blogs

garotadocampo

Duda Machado

otonome

OTONOME 〰️ Artwork Illustrations

ct-arc-echo

Echo

paladinspengler

Viola

lexaterrestrial

LEXA 🎀 TERRRESTRIAL🎀